Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics, a UK-based commercial biotechnology company specializing in allergy vaccines, has announced the appointment of Cavendish Capital Markets Limited as their new Nominated Adviser and Corporate Broker. This partnership is set to enhance the company’s financial and strategic advisory services, with Cavendish bringing in-depth knowledge of capital markets. The firm’s focus on allergy vaccine development and commercialization continues with a product line that includes treatments for a variety of allergens.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
